Fate Therapeutics Inc [FATE] Is Currently -4.55 below its 200 Period Moving Avg: What Does This Mean?

Fate Therapeutics Inc [NASDAQ: FATE] loss -4.55% or -0.22 points to close at $4.61 with a heavy trading volume of 3121648 shares. The company report on January 8, 2024 at 8:00 AM that Fate Therapeutics Announces Initiation of Phase 1 Clinical Trial for FT825 / ONO-8250 in Patients with HER2-expressing Advanced Solid Tumors.

iPSC-derived CAR T-cell Product Candidate Incorporates Seven Synthetic Controls of Cell Function including a Novel HER2-targeted Antigen Binding Domain.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Phase 1 Study is Being Conducted in Collaboration with Ono Pharmaceutical.

The daily chart for FATE points out that the company has recorded 7.71% gains over the past six months.

If we look at the average trading volume of 2.03M shares, FATE reached to a volume of 3121648 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here is what top equities market gurus are saying about Fate Therapeutics Inc [FATE]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for FATE shares is $6.32 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on FATE stock is a recommendation set at 2.58. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Wells Fargo have made an estimate for Fate Therapeutics Inc shares, keeping their opinion on the stock as Equal Weight, with their previous recommendation back on March 27, 2023.

The Average True Range (ATR) for Fate Therapeutics Inc is set at 0.38, with the Price to Sales ratio for FATE stock in the period of the last 12 months amounting to 4.28. The Price to Book ratio for the last quarter was 1.13, with the Price to Cash per share for the same quarter was set at 3.55.

Trading performance analysis for FATE stock

Fate Therapeutics Inc [FATE] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 4.77. With this latest performance, FATE shares gained by 37.61% in over the last four-week period, additionally plugging by 7.71% over the last 6 months – not to mention a drop of -16.94% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for FATE stock in for the last two-week period is set at 65.70, with the RSI for the last a single of trading hit 63.53, and the three-weeks RSI is set at 65.82 for Fate Therapeutics Inc [FATE]. The present Moving Average for the last 50 days of trading for this stock 3.23, while it was recorded at 4.60 for the last single week of trading, and 3.73 for the last 200 days.

Fate Therapeutics Inc [FATE]: A deeper dive into fundamental analysis

Fate Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 8.81 and a Current Ratio set at 8.81.

Fate Therapeutics Inc [FATE]: An earnings per share (EPS) analysis

With the latest financial reports released by the company, Fate Therapeutics Inc posted -0.58/share EPS, while the average EPS was predicted by analysts to be reported at -0.86/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 32.60%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for FATE.

An analysis of Institutional ownership at Fate Therapeutics Inc [FATE]

The top three institutional holders of FATE stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2815%. BLACKROCK INC., holding 1.03 billion shares of the stock with an approximate value of $176.59 billion in FATE stocks shares; and BERKSHIRE HATHAWAY INC, currently with $156.75 billion in FATE stock with ownership which is approximately 5.8325%.